Dr. Tan Min-Han is the founding CEO and Medical Director of Lucence Health, a medical company that delivers liquid biopsy testing for earlier cancer detection in patients. Lucence operates twin CAP and CLIA laboratories in Singapore and Palo Alto, and is the first and only Asian-headquartered healthcare company to receive United States Medicare national insurance coverage for its technology services. Lucence has supported LIQUIK, a landmark study as the world's only head-to-head prospective multicenter study evaluating liquid biopsy in cancer care.
Session:
Bespoke Healthcare (Efforts to Tailor the Healthcare Journey for Patients)12 April 2024, 1045 - 1215hrs, L1-S3
Presenting Title:
Multi-Cancer Early Detection (MCED) Blood Testing for Cancer Screening in Asia
Asia is facing a cancer tsunami in the next 30 years, with an aging population and lifestyle changes. Over 8 million new cancer cases occur in Asia annually, with the majority presenting in late stage. 78% of cancer-related deaths occur in cancers that lack effective screening methods. Compliance with traditional screening methods like mammograms are low, and availability of screening resources are limited, with limited resources to handle false positives. There is a need for accurate, accessible, and affordable approaches for earlier cancer detection, when it is most treatable. Multi-cancer early detection (MCED) blood tests are now commercially available for use in addition to traditional screening methods to address the gaps described above. This talk will discuss the development of Asia-based MCED testing to address the upcoming cancer challenges in Asia.
